Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study

Moien Ab Khan, Muhammad Jawad Hashim, Halla Mustafa, May Yousif Baniyas, Shaikha Khalid Buti Mohamad Al Suwaidi, Rana AlKatheeri, Fatmah Mohamed Khalfan Alblooshi, Meera Eisa Ali Hassan Almatrooshi, Mariam Eisa Hazeem Alzaabi, Reem Saif Al Darmaki, Shamsa Nasser Ali Hussain Lootah, Moien Ab Khan, Muhammad Jawad Hashim, Halla Mustafa, May Yousif Baniyas, Shaikha Khalid Buti Mohamad Al Suwaidi, Rana AlKatheeri, Fatmah Mohamed Khalfan Alblooshi, Meera Eisa Ali Hassan Almatrooshi, Mariam Eisa Hazeem Alzaabi, Reem Saif Al Darmaki, Shamsa Nasser Ali Hussain Lootah

Abstract

Background Ischemic heart disease (IHD) is a leading cause of death worldwide. Also referred to as coronary artery disease (CAD) and atherosclerotic cardiovascular disease (ACD), it manifests clinically as myocardial infarction and ischemic cardiomyopathy. This study aims to evaluate the epidemiological trends of IHD globally. Methods The most up-to-date epidemiological data from the Global Burden of Disease (GBD) dataset were analyzed. GBD collates data from a large number of sources, including research studies, hospital registries, and government reports. This dataset includes annual figures from 1990 to 2017 for IHD in all countries and regions. We analyzed the incidence, prevalence, and disability-adjusted life years (DALY) for IHD. Forecasting for the next two decades was conducted using the Statistical Package for the Social Sciences (SPSS) Time Series Modeler (IBM Corp., Armonk, NY). Results Our study estimated that globally, IHD affects around 126 million individuals (1,655 per 100,000), which is approximately 1.72% of the world's population. Nine million deaths were caused by IHD globally. Men were more commonly affected than women, and incidence typically started in the fourth decade and increased with age. The global prevalence of IHD is rising. We estimated that the current prevalence rate of 1,655 per 100,000 population is expected to exceed 1,845 by the year 2030. Eastern European countries are sustaining the highest prevalence. Age-standardized rates, which remove the effect of population changes over time, have decreased in many regions. Conclusions IHD is the number one cause of death, disability, and human suffering globally. Age-adjusted rates show a promising decrease. However, health systems have to manage an increasing number of cases due to population aging.

Keywords: atherosclerotic cardiovascular disease; burden of disease; cardiovascular diseases; coronary artery disease; epidemiology; global burden; ischemic heart disease; non-communicable diseases.

Conflict of interest statement

The authors have declared that no competing interests exist.

Copyright © 2020, Khan et al.

Figures

Figure 1. Global distribution of ischemic heart…
Figure 1. Global distribution of ischemic heart disease
Colors indicate prevalence rates per 100,000 population in 2017
Figure 2. Trends in the prevalence of…
Figure 2. Trends in the prevalence of ischemic heart disease using unadjusted (A) and age-standardized (B) rates
Forecast estimates using Statistical Package for the Social Sciences (SPSS) Time-Series Modeler (Ljung Box Q, p = 0.14). Dotted lines indicate upper and lower confidence limits. Age-standardization removes the effect of changes in the population age distribution (such as aging) over time and across global regions. SPSS: IBM Corp. Armonk, NY
Figure 3. Age distribution of ischemic heart…
Figure 3. Age distribution of ischemic heart disease worldwide based on prevalence (A) and incidence (B), 2017

References

    1. Heart disease and stroke statistics-2016 update. A report from the American Heart Association. Mozaffarian D, Benjamin E, Go A, et al. Circulation. 2016;133:0.
    1. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. Roth GA, Johnson C, Abajobir A, et al. J Am Coll Cardiol. 2017;70:1–25.
    1. The changing patterns of cardiovascular diseases and their risk factors in the states of India: the Global Burden of Disease Study 1990-2016. Prabhakaran D, Jeemon P, Sharma M, et al. Lancet Glob Health. 2018;6:1339–1351.
    1. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the Global Burden of Disease 2010 study. Moran AE, Forouzanfar MH, Roth GA, et al. Circulation. 2014;129:1483–1492.
    1. Frequent use of social networking sites is associated with poor psychological functioning among children and adolescents. Sampasa-Kanyinga H, Lewis RF. Cyberpsychology Behav Soc Netw. 2015;18:380–385.
    1. UN. World population prospects 2019: highlights. [Mar;2020 ]; 2019
    1. Global overview of the epidemiology of atherosclerotic cardiovascular disease. Barquera S, Pedroza-Tobías A, Medina C, et al. Arch Med Res. 2015;46:328–338.
    1. Burden of Disease. Our World Data. [Mar;2020 ];Roser M, Ritchie H. 2016
    1. Ischemic heart disease in women: facts and wishful thinking. Pepine CJ. J Am Coll Cardiol. 2004;43:1727–1730.
    1. Unfavorable and favorable changes in modifiable risk factors and incidence of coronary heart disease: the Whitehall II cohort study. Virtanen M, Vahtera J, Singh-Manoux A, Elovainio M, Ferrie JE, Kivimäki M. Int J Cardiol. 2018;269:7–12.
    1. The current cost of angina pectoris to the National Health Service in the UK. Stewart S, Murphy N, Walker A, McGuire A, McMurray J. Heart. 2003;8:848–853.
    1. The economic burden of cardiovascular disease and hypertension in low-and middle-income countries: a systematic review. Gheorghe A, Griffiths U, Murphy A, Legido-Quigley H, Lamptey P, Perel P. BMC Public Health. 2018;18:975.
    1. Institute for Health Metrics and Evaluation (IHME). GBD compare. [Dec;2019 ]; 2017
    1. Guidelines for accurate and transparent health estimates reporting: the GATHER statement. Stevens GA, Alkema L, Black RE, et al. Lancet. 2016;388:0.
    1. Principles of family medicine and general practice-defining the five core values of the specialty. Hashim MJ. J Prim Health Care. 2016;8:283–287.
    1. Mortality from ischemic heart disease: analysis of data from the World Health Organization and coronary artery disease risk factors from NCD Risk Factor Collaboration. Nowbar AN, Gitto M, Howard JP, Francis DP, Al-Lamee R. Circ Cardiovasc Qual Outcomes. 2019;12:5375.
    1. Trends in age-specific coronary heart disease mortality in the European Union over three decades: 1980-2009. Nichols M, Townsend N, Scarborough P, Rayner M. Eur Heart J. 2013;34:3017–3027.
    1. Trends in cigarette smoking among middle-aged Lithuanian subjects participating in the primary prevention program between 2009 and 2016. Rinkūnienė E, Petrulionienė Ž, Dženkevičiūtė V, et al. Medicina. 2019;55:130.
    1. Measuring success in obesity prevention: a synthesis of health promotion Switzerland’s long-term monitoring and evaluation strategy. Ackermann G, Kirschner M, Guggenbühl L, Abel B, Klohn A, Mattig T. Obes Facts. 2015;8:17–29.
    1. Cardiovascular disease prevention in eastern Europe. Ginter E. Nutrition. 1998;14:452–457.
    1. Trends in life expectancy in EU and other OECD countries. Raleigh VS. 2019;108:60.
    1. Association of myocardial infarction with stressful life events and psychiatric symptoms: a population-based survey. Hatmi Z, Nasiri L, Sadegianmehr Z, Mirkia S, Darbooy S. East Mediterr Health J. 2011;17:398–403.
    1. Life expectancy and cause of death in the Kuwaiti population 1987-2000. El Shazly M, Makboul G, El Sayed A. East Mediterr Health J. 2004;10:45–55.
    1. Welfare state regimes, unemployment and health: a comparative study of the relationship between unemployment and self-reported health in 23 European countries. Bambra C, Eikemo TA. J Epidemiol Community Health. 2009;63:92–99.
    1. The impact of socio-economic status on self-rated health: study of 29 countries using European social surveys (2002-2008) Alvarez-Galvez J, Rodero-Cosano ML, Motrico E, Salinas-Perez JA, Garcia-Alonso C, Salvador-Carulla L. Int J Environ Res Public Health. 2013;10:747–761.
    1. Burden of non-communicable diseases in sub-Saharan Africa, 1990-2017: results from the Global Burden of Disease Study 2017. Gouda HN, Charlson F, Sorsdahl K, et al. Lancet Glob Health. 2019;7:1375–1387.
    1. Cardiovascular disease in the Eastern Mediterranean region: epidemiology and risk factor burden. Turk-Adawi K, Sarrafzadegan N, Fadhil I, et al. Nat Rev Cardiol. 2018;15:106.
    1. Association of smoking cessation with subsequent risk of cardiovascular disease. Duncan MS, Freiberg MS, Greevy RA, Kundu S, Vasan RS, Tindle HA. JAMA. 2019;322:642–650.
    1. Metabolic syndrome from adolescence to early adulthood: effect of infancy-onset dietary counseling of low saturated fat: the Special Turku Coronary Risk Factor Intervention Project (STRIP) Nupponen M, Pahkala K, Juonala M, et al. Circulation. 2015;131:605–613.
    1. Potential impact of a modest reduction in salt intake on blood pressure, cardiovascular disease burden and premature mortality: a modelling study. Aminde LN, Cobiac LJ, Veerman JL. Open Heart. 2019;6:0.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться